Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Christina Pfeiffer, Alexander Michael Grandits, Hélène Asnagli, Anja Schneller, Julia Huber, Niklas Zojer, Martin Schreder, Andrew Parker, Arnold Bolomsky, Philip Beer, Heinz Ludwig

Blood (2022) 140 (Supplement 1): 7088–7089.

https://doi.org/10.1182/blood-2022-160333

Published: 2022

Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Blood (2021) 138 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2021-150311

Published: 2021

Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140918

Published: 2020

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Blood (2019) 134 (Supplement_1): 1358.

https://doi.org/10.1182/blood-2019-125262

Published: 2019

Journal Articles

Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma

Arnold Bolomsky, Fred Gruber, PhD, Kathrin Stangelberger, MSc, Leon Furchtgott, PhD, Dominik Arnold, Puja Raut, Diane Wuest, PhD, Karl Runge, Iya Khalil, Niklas Zojer, MD, Nikhil Munshi, MD, Boris Hayete, PhD, Heinz Ludwig, MD

Blood (2018) 132 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2018-99-117886

Published: 2018

Journal Articles

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Heinz Ludwig, MD, Wolfram Pönisch, MD, Stefan Knop, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, MD PhD, Eberhard Gunsilius, MD, Karl Jochen Krenosz, MD, Andreas Petzer, MD, Katja Weisel, MD, Hermann Einsele, MD PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2018) 132 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2018-99-118061

Published: 2018

Journal Articles

Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population

Dean Bryant, Will Tapper, Nicola J. Weston-Bell, Arnold Bolomsky, Li Song, Shengtao Xu, Andrew R. Collins, Niklas Zojer, Surinder Singh Sahota

Blood (2018) 132 (2): 232–235.

https://doi.org/10.1182/blood-2018-01-829291

Published: 2018

Includes: Supplemental data

Journal Articles

Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma

Arnold Bolomsky, PhD, Roy Heusschen, PhD, Kathrin Stangelberger, MSc, Muller Joséphine, Marla Weetall, PhD, Art Branstrom, PhD, Niklas Zojer, MD, Jo Caers, MD, Heinz Ludwig, MD

Blood (2017) 130 (Supplement 1): 1804.

https://doi.org/10.1182/blood.V130.Suppl_1.1804.1804

Published: 2017

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Heinz Ludwig, MD, Wolfram Pönisch, MD, Alexander Egle, MD, Stefan Knop, MD, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, Eberhard Gunsilius, Michael A. Fridrik, MD, Andreas Petzer, MD, Katja C. Weisel, Dietger Niederwieser, MD, Axel Hinke, PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2017) 130 (Supplement 1): 1857.

https://doi.org/10.1182/blood.V130.Suppl_1.1857.1857

Published: 2017

Journal Articles

Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma

Arnold Bolomsky, PhD, Roy Heusschen, PhD, Karin Schlangen, PhD, Kathrin Schönfelder, MSc, Joséphine Muller, MSc, Wolfgang Schreiner, PhD, Niklas Zojer, MD, Jo Caers, Heinz Ludwig, MD

Blood (2016) 128 (22): 309.

https://doi.org/10.1182/blood.V128.22.309.309

Published: 2016

Journal Articles

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Blood (2016) 128 (22): 1066.

https://doi.org/10.1182/blood.V128.22.1066.1066

Published: 2016

Journal Articles

Single Cell Whole Exome Sequencing in an Index Case of Amp1q21 Multiple Myeloma to Define Intraclonal Variation

Dean Bryant, PhD, Will Tapper, PhD, Nicola J Weston-Bell, PhD, Arnold Bolomsky, PhD, Li Song, PhD, Shengtao Xu, B.Sc, Andrew R Collins, PhD, Niklas Zojer, MD, Surinder Singh Sahota, PhD

Blood (2016) 128 (22): 5651.

https://doi.org/10.1182/blood.V128.22.5651.5651

Published: 2016

Journal Articles

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Heinz Ludwig, MD, Eberhard Gunsilius, MD, Michael Fridrik, MD, Richard Greil, Andreas Petzer, MD, Thomas Kühr, Univ. Doz. Dr., Stefan Knop, MD, Martin Schreder, MD, Elisabeth Rauch, Mag., Wolfram Poenisch, MD, Niklas Zojer, MD

Blood (2016) 128 (22): 3335.

https://doi.org/10.1182/blood.V128.22.3335.3335

Published: 2016

Journal Articles

Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma

Arnold Bolomsky, Karin Schlangen, Artur Köhler, Goran Mitulovic, Wolfgang Schreiner, Niklas Zojer, MD, Heinz Ludwig

Blood (2015) 126 (23): 1823.

https://doi.org/10.1182/blood.V126.23.1823.1823

Published: 2015

Journal Articles

Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma

Heinz Ludwig, Univ. Prof. Dr., Katja Weisel, MD, Maria Teresa Petrucci, MD, Xavier Leleu, MD, Anna Maria Cafro, MD, Garderet Laurent, MD, Niklas Zojer, MD, Robin Foa, MD, Richard Greil, MD, Ibrahim Yakoub-Agha, MD PhD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 2111.

https://doi.org/10.1182/blood.V124.21.2111.2111

Published: 2014

Journal Articles

CXCR3 Binding Chemokines MIG, IP-10 and ITAC Are Predictors of Overall Survival in Newly Diagnosed Multiple Myeloma

Arnold Bolomsky, Niklas Zojer, MD, Martin Schreder, MD, Heinz Ludwig, Univ. Prof. Dr.

Blood (2014) 124 (21): 2052.

https://doi.org/10.1182/blood.V124.21.2052.2052

Published: 2014

Journal Articles

Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

Blood (2014) 124 (21): 280.

https://doi.org/10.1182/blood.V124.21.280.280

Published: 2014

NARROW

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population

Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Single Cell Whole Exome Sequencing in an Index Case of Amp1q21 Multiple Myeloma to Define Intraclonal Variation

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma

Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma

CXCR3 Binding Chemokines MIG, IP-10 and ITAC Are Predictors of Overall Survival in Newly Diagnosed Multiple Myeloma

Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only